Inactive Instrument

Calendar Wilex AG Xetra

Equities

DE0006614720

End-of-day quote Xetra
- EUR - Intraday chart for Wilex AG

Chart calendar Wilex AG

d83.IlraJU68Pm9BgCTBfn_rp0cufz0l1PKKaE-Ga3J54x0.aS2rXQrITzxsymjzKTO54nJpKHNLl4LhHDiwLDUmj2pHLptSCfYMXwPnEA~7698a9f31a8b8aba8db5feb9bf45bf23

Upcoming events on Wilex AG

28/07/2024 GRC Natural Products and Bioactive Compounds Conference
25/08/2024 European Peptide Symposium
01/09/2024 Medicinal Chemistry International Symposium
03/10/2024 Q3 2024 Earnings Release (Projected)
09/10/2024 BIO Japan Conference
10/10/2024 11:30 am Q3 2024 Sales and Revenue Release - Interim Management Statement
15/10/2024 Festival of Biologics Conference
20/10/2024 HUPO World Congress
04/11/2024 World ADC San Diego Conference
05/11/2024 PEGS Europe Conference
07/12/2024 American Society of Hematology and Exposition Meeting
10/07/2025 Q2 2025 Earnings Release (Projected)

Past events on Wilex AG

11/07/2024 10:35 am Q2 2024 Earnings Release
25/06/2024 World ADC Asia Conference
20/06/2024 02:30 pm Annual General Meeting
04/06/2024 Jefferies Global Healthcare Conference
04/06/2024 Antibody Engineering & Therapeutics Europe Conference
03/06/2024 BIO International Convention
01/06/2024 12:30 am Oncology Innovation Forum
31/05/2024 09:15 pm Oncology Innovation Forum - Panel
31/05/2024 09:15 pm Oncology Innovation Forum - Panel
31/05/2024 American Society of Clinical Oncology Meeting
21/05/2024 ADC Payload Summit
13/05/2024 PEGS Boston Conference
25/04/2024 11:30 am Q1 2024 Sales and Revenue Release - Interim Management Statement
23/04/2024 07:30 pm R&D Day
16/04/2024 Kempen Life Science Conference
16/04/2024 German Biotechnology Conference
10/04/2024 09:30 pm American Association for Cancer Research Meeting - Abstract No 7183
08/04/2024 09:30 pm American Association for Cancer Research Meeting - Abstract No 1865
08/04/2024 09:30 pm American Association for Cancer Research Meeting - Abstract No CT067
08/04/2024 02:00 am American Association for Cancer Research Meeting - Abstract No :LB059

Annual results

Fiscal PeriodNovember 2019 2020 2021 2022 2023 2024
Net sales
Million EUR
Released
Forecast
Spread
7,96
8,63
-7.75%
9,58
9,70
-1.28%
2,31
2,31
0.13%
19,9
19,4
2.27%
16,8
13,8
21.75%

11,5

EBITDA
Million EUR
Released
Forecast
Spread
-9,60
-8,08
-18.83%
-17,6
-15,1
-16.55%
-24,8
-23,2
-7.14%
-16,4
-18,2
9.58%
-20,3
-31,1
34.63%

-22,1

EBIT
Million EUR
Released
Forecast
Spread
-10,1
-8,57
-18.4%
-18,3
-15,8
-15.97%
-25,6
-24,6
-4.27%
-17,2
-19,9
13.62%
-21,2
-32,0
33.72%

-22,6

Earnings before Tax (EBT)
Million EUR
Released
Forecast
Spread
-10,1
-8,30
-22.21%
-18,3
-14,9
-22.72%
-26,1
-24,7
-5.84%
-17,8
-20,3
12.29%
-20,3
0,00
-

0,00

Net income
Million EUR
Released
Forecast
Spread
-10,1
-8,30
-22.27%
-18,3
-14,9
-22.72%
-26,1
-24,9
-5.04%
-19,7
-20,0
1.67%
-20,3
0,00
-

0,00

EPS
EUR
Released
Forecast
Spread
-0,36
-0,30
-19.44%
-0,61
-0,54
-13.45%
-0,80
-0,72
-10.81%
-0,53
-0,64
17.46%
-0,44
-0,72
38.89%

-0,30

Announcement Date19/03/2025/03/2124/03/2205/03/2325/03/24-